A retrospective study involving 80 patients with advanced HCC receiving ICIs demonstrated significant elevations in IL-8 levels among those failing to achieve disease control after the initial dose of immunotherapy and prior to the second dose [52]. This evidence concerns the gene CXCL8 and hepatocellular carcinoma.